Status:

RECRUITING

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

Lead Sponsor:

University of Maryland, Baltimore

Conditions:

Pain

Virtual Reality

Eligibility:

All Genders

18-88 years

Phase:

PHASE1

PHASE2

Brief Summary

This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for ...

Detailed Description

Virtual reality (VR) has been seen as an intervention for alleviating clinical chronic (and acute) pain. An approach to pain management utilizing VR presents opportunities for reducing pain and suffer...

Eligibility Criteria

Inclusion

  • Age (18-88 years)
  • English speaker (written and spoken)
  • Temporal Mandibular Disorder (TMD) for at least 3 months

Exclusion

  • Present or past degenerative neuromuscular disease
  • Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years
  • Cervical pain other than TMD related (e.g. stenosis, radiculopathy)
  • Any personal (or family first degree) history of mania, schizophrenia, or other psychoses
  • Severe psychiatric condition (e.g., schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.
  • Use of antidepressants, ADHD medication, non-over-the-counter painkillers, methadone, benzodiazepines, barbiturates, and/or narcotics during the past 3 months
  • Lifetime alcohol/drug dependence or alcohol/drug abuse in the past 3 months
  • Pregnancy or breastfeeding
  • Color-blindness
  • Pain in jaw or temple in last 3 months due to toothache or infection
  • Any facial trauma that has occurred in the last 6 weeks
  • History of severe facial trauma in the last 3 months
  • Impaired or uncorrected hearing
  • Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection)
  • Known history of severe motion sickness
  • High blood pressure or symptomatic low blood pressure
  • History of fainting
  • History of angioedema
  • Failed drug test (testing for opiates, cocaine, methamphetamines, amphetamines, and THC)

Key Trial Info

Start Date :

November 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2026

Estimated Enrollment :

259 Patients enrolled

Trial Details

Trial ID

NCT04851301

Start Date

November 1 2021

End Date

November 30 2026

Last Update

June 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Luana Colloca

Baltimore, Maryland, United States, 21201-1512